Similar results targeting cancer stem cells with the polyketide antibiotic, Mithraymcin-A, and ICI in a CRC mouse model resulted in turning an immunologically cold tumor hot by increasing CD8+ T-cell infiltration and decreasing quantities of MDSC/TAMs in the TME [196]. This evidence concerns the gene CD8A and neoplasm.